Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab maintenance in pMMR advanced or recurrent endometrial carcinoma
NL-OMON59748Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in endometrial cancer (EC) comparing Maintenance sacituzumab tirumotecan plus pembrolizumab with Maintenance pembrolizumab alone (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59748.